ALK and non-small cell lung carcinoma: Following the discovery of ALK-driven NSCLC in ~5–10% of the patient population (Soda et al., 2007), Pfizer proceeded with utilizing a fluorescence in situ hybridization (FISH) assay to detect the ALK chromosomal translocation as an eligibility requirement for patient enrollment.